{"id":"mpl-001-cbd-thc-25-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Altered appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines cannabidiol (CBD) and tetrahydrocannabinol (THC) in a fixed 25:1 ratio. CBD acts as a partial agonist at CB1 and CB2 receptors and modulates serotonin and vanilloid receptors, while THC is a CB1/CB2 agonist. The high CBD-to-THC ratio is designed to maximize therapeutic benefits while minimizing psychoactive effects associated with THC.","oneSentence":"MPL-001 is a cannabinoid combination product that modulates endocannabinoid signaling through CBD and THC at a 25:1 ratio to produce therapeutic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:17.510Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05351905","phase":"NA","title":"Improving Pain Disability With the Use of Oral Cannabinoids","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2022-11-22","conditions":"Chronic Pain, Opioid Use, Cannabis","enrollment":51},{"nctId":"NCT05754840","phase":"PHASE1, PHASE2","title":"CANnabinoids in Pediatric ONCology","status":"NOT_YET_RECRUITING","sponsor":"University of Manitoba","startDate":"2025-06","conditions":"Childhood Cancer, Cancer","enrollment":60},{"nctId":"NCT03825965","phase":"PHASE3","title":"Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT","status":"COMPLETED","sponsor":"McMaster University","startDate":"2023-05-03","conditions":"Knee Osteoarthritis","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MPL-001 (CBD: THC 25:1)","genericName":"MPL-001 (CBD: THC 25:1)","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}